Zhang Y, Liu X, Deng M, Xu C, Zhang Y, Wu D, et al
Glucagon-like peptide-1 (GLP-1) receptor agonistsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)along with tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist, have transformed the management of type 2 diabetes and obesity
This is particularly relevant in the cancer context, where the tumor microenvironment often promotes oxidative stress and altered cellular signaling pathways, contributing to the rapid turnover of RBCs
Prepare smaller batches if your protocol allows some users report reduced efficacy after 2 weeks
ITF-2357 has advanced in multiple clinical trials, with recent progress in some indications